iptacopan
Sponsor Novartis AG · listed as NVS
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
iptacopan is a clinical-stage drug asset sponsored by Novartis AG, listed as NVS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Apr 30, 2027 (day precision, medium confidence), tied to trial NCT06517758. The asset is in Phase 3 and currently recruiting, studied in Generalized Myasthenia Gravis.
Next catalyst
Event typeREADOUT
Expected date2027-04-30
As disclosedApr 30, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06517758
PhasePHASE3
StatusRECRUITING
Lead sponsorNovartis Pharmaceuticals
Listed asNVS
Condition(s)Generalized Myasthenia Gravis
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More NVS catalysts